Warburg Pincus, a global growth investor, has acquired Pharma Intelligence, a provider of specialist intelligence, data and software for clinical trials, drug development and regulatory compliance, from Informa Plc. Additionally, Mubadala Investment Co. will join Warburg Pincus in the investment.

Pharma Intelligence is an operator in the global pharma and life sciences analytics markets. The firm provides insights on patient enrollment and demographics, trial progress, individual trial sites and investigators for over 375,000 clinical trials in 180 countries. The deal will include Informa’s portfolio of specialist brands including Citeline, Trialtrove, Siterove, Pharmaprojects and more.

“We received significant interest in the Pharma Intelligence business,” stated Stephen Carter, group chief executive, Informa PLC. “We are delighted to partner with Warburg Pincus and share their view on its future growth potential, hence, we welcomed an agreement that represented value today and growth and value tomorrow.’’

‘’Pharma Intelligence’s services are of vital importance to the pharma, biotech, and healthcare community,” commented Jay Nadler, senior adviser to Warburg Pincus. “It’s a fast-growing company with outstanding products and people, and a commitment to best-in-class service with deep expertise in sectors that Warburg Pincus understands extremely well. We look forward to partnering with the company’s employees and customers, working together to drive innovation to introduce more efficiency into the drug development lifecycle.’’